1132827-21-4

Basic information

• Product Name: AC 010220 (dihydrochloride)
• Synonyms: AC 010220 (dihydrochloride);AC 220 dihydrochloride;Quizartinib dihydrochloride;Quizartinib HCl;1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea:dihydrochloride
• CAS NO: 1132827-21-4
• Molecular Formula: C29H34Cl2N6O4S
• Molecular Weight: 633.58906
• Mol File: 1132827-21-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AC 010220 (dihydrochloride)(CAS DataBase Reference)
• NIST Chemistry Reference: AC 010220 (dihydrochloride)(1132827-21-4)
• EPA Substance Registry System: AC 010220 (dihydrochloride)(1132827-21-4)

Safety Data

• Hazardous Substances Data: 1132827-21-4(Hazardous Substances Data)

Usage

General Description

AC 010220 (dihydrochloride) is a chemical compound used in scientific research as a selective antagonist for the muscarinic acetylcholine receptor M1. It has been studied for its potential therapeutic applications in treating neurological and psychiatric disorders, including Alzheimer's disease, schizophrenia, and other cognitive impairments. AC 010220 (dihydrochloride) has shown promise in preclinical studies for its ability to modulate cholinergic neurotransmission and improve cognitive function, making it a subject of interest for further exploration in drug development. Its specificity for the M1 receptor also makes it a valuable tool for studying the role of this receptor in various physiological and pathological processes.

Upstream product

• 55809-36-4 3-amino-5-tert-butylisoxazole 
• 1747-60-0 6-methoxybenzothiazol-2-ylamine 
• 26278-79-5 2-amino-6-hydroxybenzothiazole 
• 914224-34-3 2-(4-nitrophenyl)imidazo[2,1-b][1,3]benzothiazol-7-ol 
• 950769-60-5 4-(2-((2-(4-nitrophenyl)benzo[d]imidazo[2,1-b]thiazol-7-yl)oxy)ethyl)morpholine 
• 950769-58-1 quizartinib 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES

Provided herein are process for the preparation of N-(5-ferf-butyl-isoxazol-3-yl)- N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,l-fe][l,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt, solvate, hydrate, or polymorph thereof. N-(5-tert- Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,l-and][l,3]benzo- thiazol-2-yl]phenyl}urea is useful for treating, preventing, and/or managing diseases or conditions, including but not limited to, proliferative diseases, FLT-3 mediated diseases, and cancers. N-(5-ferf-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl- ethoxy)imidazo[2,l-and][l,3]benzothiazol-2-yl]phenyl}urea is represented by the structure:

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2- morpholin-4-yl-ethoxy)imidazo-[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor

Treatment of AML patients with small molecule inhibitors of FLT3 kinase has been explored as a viable therapy. However, these agents are found to be less than optimal for the treatment of AML because of lack of sufficient potency or suboptimal oral pharma